THE ROLE OF PSYCHOLOGICAL VARIABLES FOR TYROSINE KINASE INHIBITORS (TKI) DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: IMPLICATION FOR MEDICAL DECISION MAKING PRACTICE
EHA Learning Center, Alessandra Lurlo and Cristina Buccelli, 182016
BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28 EU MEMBER STATES
EHA Learning Center, Fanni Rencz, 182017
ALLO-HCT FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - 12 YEARS OF EXPERIENCE
EHA Learning Center, Miroslaw Markiewicz, 182028
A COMPARISON OF CLINICAL OUTCOMES BETWEEN MATCHED SIBLING DONOR (MSD) AND UNRELATED DONOR (URD) STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA
EHA Learning Center, Seunghwan Shin, 182029
HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANT IN SEVERE THALASSEMIA PATIENTS
EHA Learning Center, Suradej hongeng, 182030
AUGMENTATION OF FLUDARABINE AND BUSULFAN-BASED MYELOABLATIVE REGIMEN WITH THIOTEPA IMPROVES OUTCOMES WITH NO ADDED TOXICITY IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA
EHA Learning Center, Vipul SHETH, 182031
PROGNOSTIC TOOLS CAN PROVIDE PERSONALIZED OUTCOMES PREDICTION AFTER ALLOGENEIC HCT IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
EHA Learning Center, Christina CHO, 182032
THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: IS THERE A PROTECTIVE ROLE FOR URSODEOXYCHOLIC ACID?
EHA Learning Center, Rocio Parody Porras, 182033
MESENCHYMAL STEM CELLS (MSCS) ATTENUATE CUTANEOUS SCLERODERMATOUS GRAFT-VERSUS-HOST DISEASE (SCL-GVHD) THROUGH INHIBITION OF IMMUNE CELL INFILTRATION IN A MOUSE MODEL
EHA Learning Center, Ji-Young Lim, 182044
C57BL/6 SUBTRAINS SHOW DIFFERENCES IN HEMATOPOIETIC REPOPULATION
EHA Learning Center, Antonio Morales Hernandez, 182045
GWAS RESULTS IN RED BLOOD CELL PHENOTYPES AND THEIR RELATIONSHIP WITH THROMBOSIS
EHA Learning Center, Angel F Remacha, 182046
ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS SHOW AN INCREASED THROMBUS FORMATION IN A DYNAMIC MODEL OF PLATELET ADHESION
EHA Learning Center, Alfonso Vignoli, 182047
DOAC ASSOCIATED MAJOR GASTROINTESTINAL BLEEDING: REAL LIFE EXPERIENCE FROM A UNIVERSITY TEACHING HOSPITAL, UK
EHA Learning Center, Buddhika Badugama, 182048
INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING LOWER LIMB SURGICAL REVASCULARIZATION: IS THROMBOPROPHYLAXIS WARRANTED?
EHA Learning Center, Anmol Baranwal, 182050
CYSTEINE AND GLYCINE-RICH PROTEIN 2 (CSPR2) TRANSCRIPT LEVELS CORRELATE WITH LEUKEMIA RELAPSE AND LEUKEMIA-FREE SURVIVAL IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH NORMAL CYTOGENETICS
EHA Learning Center, Shu-Juan Wang, 181798
THERAPEUTIC TARGETING OF PRE-B CELL RECEPTOR SIGNALLING IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Ali Alhammer, 181799
BMP-4 LEVELS IN CHILDHOOD B-ALL OF LOW-/INTERMEDIATE-RISK GROUPS IDENTIFY CHILDREN WITH POOR OUTCOME
EHA Learning Center, Lidia M Fernández-Sevilla, 181800
TARGETING LOCALIZATION OF THE IL-7 RECEPTOR WITHIN LIPID RAFTS AS A THERAPEUTIC STRATEGY FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Anne BUFFIERE, 181801
SYSTEMATIC MRI SCREENING IDENTIFIES EXTENSIVE ASYMPTOMATIC OSTEONECROTIC LESIONS IN ADOLESCENTS WITH ALL - FIRST INTERIM FINDINGS OF THE OPAL TRIAL
EHA Learning Center, Marina Kunstreich, 181802
FINAL ANALYSIS OF A RANDOMIZED STUDY COMPARING PROPHYLACTIC AND MRD-TRIGGERED, PRE-EMPTIVE IMATINIB AFTER HSCT FOR PH+/BCR-ABL1 POSITIVE ALL: LONG-TERM PATIENT OUTCOME AND IMPLICATIONS OF MRD ANALYSIS
EHA Learning Center, Dr. Fabian Lang, 181803
THE MIXED LINEAGE LEUKEMIA FUSION PARTNER ENL RECRUITS PAF1 TO CLEAR POLYCOMB-INDUCED TRANSCRIPTIONAL REPRESSION
EHA Learning Center, Robert Slany, 181814
PKC EPSILON SUPPORTS ACUTE MYELOID LEUKEMIA BY MAINTAINING MITOCHONDRIAL REDOX HOMEOSTASIS.
EHA Learning Center, Daniela Di Marcantonio, 181815
ROLE OF SHP2 IN A MOUSE MODEL OF AML CARRYING FLT3-ITD ALONG WITH LOSS OF TET2
EHA Learning Center, Ruchi Pandey, 181817
CLUSTER REGULATION OF RUNX FAMILY BY “GENE SWITCH” TRIGGERS A PROFOUND TUMOR REGRESSION OF DIVERSE ORIGINS.
EHA Learning Center, Ken Morita, 181818
PHOSPHOPROTEOMICS AND MASS CYTOMETRY SIGNATURES OF PRIMARY AML CELL DIFFERENTIATION ARE ASSOCIATED WITH SENSITIVITY TO KINASE INHIBITORS
EHA Learning Center, Pedro Casado-Izquierdo, 181819
CLINICAL IMPACT OF TET2 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS HARBORING CEBPA MUTATIONS: A STUDY OF THE AML STUDY GROUP (AMLSG)
EHA Learning Center, Frauke Theis, 181820
PROFILING THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA AT RELAPSE AFTER CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.
EHA Learning Center, Elisa Sala, 181831
AML PATIENTS AGED ≥75 YEARS ENROLLED INTO AMLCG TRIALS: DO GENETIC ALTERATIONS IMPACT CLINICAL OUTCOME IN VERY OLD, INTENSIVELY TREATED PATIENTS?
EHA Learning Center, Victoria Prassek, 181833
GMI-1271, A POTENT E-SELECTIN ANTAGONIST, IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED/REFRACTORY AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE
EHA Learning Center, Daniel J. DeAngelo, 181834
BST 236, A NOVEL CYTARABINE PRO-DRUG ALLOW, FOR THE FIRST TIME, THE DELIVERY OF HIGH CYTARABINE DOSES FOR OLDER OR UNFIT PATIENTS WITH ACUTE LEUKEMIA. RESULTS OF AN ONGOING PHASE I/IIA STUDY
EHA Learning Center, Tsila Zuckerman, 181835
FEASIBILITY AND BENEFIT OF TARGETED RNA SEQUENCING FOR THE DETECTION OF RECURRENT FUSION TRANSCRIPTS AND THE IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS IN MYELOID MALIGNANCIES
EHA Learning Center, Claudia Haferlach, 181836
COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)
EHA Learning Center, Kiyomi Morita, 181837
CLINICAL OUTCOME OF HYPOCELLULAR AML AND AML WITH MYELODYSPLASIA-RELATED CHANGE (MRC) COMPARED TO DE NOVO ADULT AML WITH NORMAL CELLULARITY AFTER HEMATOPOIETIC CELL TRANSPLANTATION
EHA Learning Center, Daehun kwak, 181848
INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML
EHA Learning Center, Jorge Cortes, 181849
COMBINATION OF TGR-1202, UBLITUXIMAB, AND BENDAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA
EHA Learning Center, Matthew A. Lunning, 181850
VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)
EHA Learning Center, Matthew S. Davids, 181851
WHOLE BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IS A GOOD PREDICTOR OF TREATMENT OUTCOME AFTER ONE CYCLE OF IMMUNOCHEMOTHERAPY IN AGGRESSIVE LYMPHOMA
EHA Learning Center, Katja De Paepe, 181852
PREVALENCE AND PROGNOSTIC VALUE OF MYD88 AND CD79B MUTATIONS IN IMMUNE-PRIVILEGED SITE AND (EXTRA)NODAL DLBCLS.
EHA Learning Center, Joost Vermaat, 181854
DIAMOND-BLACKFAN ANEMIA IN THE NETHERLANDS: AN OVERVIEW OF CLINICAL CHARACTERISTICS AND UNDERLYING MOLECULAR DEFECTS.
EHA Learning Center, Birgit van Dooijeweert, 181866
NEXT GENERATION SEQUENCING IN BONE MARROW FAILURE SYNDROMES
EHA Learning Center, Eva Galvez, 181867
APLASTIC ANEMIA PATIENTS WITH MONOCYTE-DOMINANT PNH CLONES HAVE A UNIQUE PRESENTATION AND ARE LESS RESPONSIVE TO IMMUNOSUPPRESSIVE THERAPY
EHA Learning Center, Emilie Nevill, 181868
RESPONSE TO ANTI-THYMOCYTE GLOBULIN (ATG) IN PATIENTS WITH APLASTIC ANEMIA (AA): A SINGLE-CENTRE EXPERIENCE OVER THE LAST 28 YEARS
EHA Learning Center, Maren Oelmüller, 181869
NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS
EHA Learning Center, Federico Pozzo, 181870
CLL-LIKE B-CELL CLONES FROM MBLLO INDIVIDUALS PERSIST AT INCREASED COUNTS AFTER SEVEN YEARS OF FOLLOW-UP.
EHA Learning Center, Julia Almeida, 181871
INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE
EHA Learning Center, Sieghart Sopper, 181882
BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB
EHA Learning Center, Konstantin Byrgazov, 181883
IS THERE EFFECTIVE IMMUNE SURVEILLANCE AGAINST CHRONIC MYELOID LEUKAEMIA? NO.
EHA Learning Center, Robert Peter Gale, 181884
MUTATIONAL ANALYSIS IN BCR-ABL1 POSITIVE LEUKEMIA BY DEEP SEQUENCING BASED ON NANOPORE MINION TECHNOLOGY
EHA Learning Center, Francesco Albano, 181885
THE AUTOMATED MOLECULAR TECHNIQUE “ULTRA” ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA.
EHA Learning Center, sara galimberti, 181886
ROLE OF THE AURORA KINASE A/PLK 1 AXIS INHIBITION IN RESTORATION OF CELL GROWTH CONTROL OF CHRONIC MYELOID LEUKEMIA PROGENITORS
EHA Learning Center, Manuela Mancini, 181887
THE EUROPE AGAINST CANCER PROTOCOL FOR BCR-ABL P210 TRANSCRIPT MEASUREMENT MAY OVERESTIMATE RESULTS FOR E13A2 VARIANT
EHA Learning Center, Michal Gniot, 181898
ESTABLISHMENT OF IN VIVO AND IN VITRO MODEL OF X-LINKED SIDEROBLASTIC ANEMIA
EHA Learning Center, Kei Saito, 181899
BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY FOR COLD AGGLUTININ DISEASE: RESULTS OF A PROSPECTIVE NORDIC TRIAL.
EHA Learning Center, Sigbjorn Berentsen, 181900
EX VIVO TREATMENT OF RED BLOOD CELLS FROM 15 PYRUVATE KINASE (PK)-DEFICIENT PATIENTS WITH AG-348, AN ALLOSTERIC ACTIVATOR OF PK-R, INCREASES ENZYMATIC ACTIVITY, PROTEIN STABILITY AND ATP LEVELS.
EHA Learning Center, Richard van Wijk, 181901
IDENTIFICATION OF NEW PATHOGENIC MUTATIONS IN PATIENTS WITH RED BLOOD CELL MEMBRANE DISORDERS USING NEXT-GENERATION SEQUENCING
EHA Learning Center, Maria Del Mar MAÑU PEREIRA, 181902
CLINICAL FOLLOW-UP OF 378 PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: PROGNOSTIC IMPACT OF HEMOGLOBIN LEVELS, AUTOANTIBODY CLASS, AND RETICULOCYTOPENIA AT ONSET ON THE RELAPSE RISK AND OUTCOME
EHA Learning Center, Bruno Fattizzo, 181903
PRECLINICAL TESTING OF ADOPTIVE T-CELL RECEPTOR GENE TRANSFER IN COMBINATION WITH CHECKPOINT INHIBITORS AS A NOVEL THERAPY FOR MULTIPLE MYELOMA
EHA Learning Center, Hakim Echchannaoui, 181914
EXPLORING HUMAN TCR- AND CAR-REDIRECTED INKT CELLS FOR ADOPTIVE CELLULAR THERAPY
EHA Learning Center, Udo Hartwig, 181916
SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF ENGINEERED CIK (CYTOKINE-INDUCED KILLER) CELLS EXPRESSING THE ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR (CAR).
EHA Learning Center, Maria Caterina Rotiroti, 181917
UPDATE ON THE FIRST PATIENTS WITH SEVERE HEMOGLOBINOPATHIES TREATED WITH LENTIGLOBIN GENE THERAPY
EHA Learning Center, Marina Cavazzana, 181918
A SINGLE INSTITUTIONAL EXPERIENCE OF 261 PATIENTS WITH LARGE GRANULAR LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Magali Van den Bergh, 181919
ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K-DELTA INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (CITADEL-101)
EHA Learning Center, Andres Forero-Torres, 181920
PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS
EHA Learning Center, John Burke, 181921
CHARACTERISTICS AND OUTCOME OF PULMONARY INFILTRATES IN ACUTE LEUKEMIA CLASSIFIED ACCORDING TO EORTC/MSG CRITERIA OF INVASIVE FUNGAL INFECTION: A PROSPECTIVE STUDY BY THE RETE EMATOLOGICA LOMBARDA
EHA Learning Center, Chiara Cattaneo, 181931
ANTIFUNGAL PROPHYLAXIS WITH CD101 IN IMMUNOSUPPRESSED MOUSE MODELS OF CANDIDIASIS, ASPERGILLOSIS, AND PNEUMOCYSTIS PNEUMONIA (PCP)
EHA Learning Center, Voon Ong, 181932
SURGICAL MANAGEMENT OF INVASIVE FUNGAL INFECTIONS IN ADULT LEUKAEMIA PATIENTS - EXPERIENCE FROM A LARGE TERTIARY CENTRE IN SOUTH-EAST ASIA
EHA Learning Center, yan chin tan, 181933
INFECTIONS IN MULTIPLE MYELOMA ARE FREQUENT AND PREDOMINANTLY CAUSED BY BACTERIA: RESULTS OF A 12-YEAR SURVEY FROM A SINGLE CENTER
EHA Learning Center, Marie VON LILIENFELD-TOAL, 181934
HUMAN L-FICOLIN POLYMORPHISMS CONTRIBUTE TO SUSCEPTIBILITY TO INFECTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Ulf Schnetzke, 181935
PREDICTIVE FACTORS OF RESPONSE TO EPOETIN THETA IN CHEMOTHERAPY-INDUCED ANEMIA: A FRENCH MULTICENTER OBSERVATIONAL STUDY (PIVOINE).
EHA Learning Center, Philippe Rodon, 181936
TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER PRIMARY CHEMOTHERAPY: EXPLORATORY ANALYSIS OF AN EXPANDED-ACCESS PROTOCOL
EHA Learning Center, Paul Richardson, 181937
TRANSCRIPTOME ASSESSMENT OF DNA REPAIR GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA: SYNTHETIC LETHALITY TARGETS
EHA Learning Center, Ana María Hurtado López, 181947
DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND NON-CLONAL CYTOPENIAS BY FLOW CYTOMETRY ANALYSIS USING A MYELOID MATURATION DATABASE
EHA Learning Center, Maria Teresa Cedena, 181948
A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Aaron T. Gerds, 181949
EPIGENETIC DRUG TREATMENT GLOBALLY INDUCES CRYPTIC TRANSCRIPTION START SITES ENCODED IN LONG TERMINAL REPEATS (LTRS)
EHA Learning Center, Michael Daskalakis, 181950
LYMPHOPENIA IS AN INDEPENDENT RISK-FACTOR IN PATIENTS WITH LOW-RISK MDS ACCORDING TO THE IPSS-R
EHA Learning Center, Tobias Silzle, 181951
IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS
EHA Learning Center, Ana Alfonso Pierola, 181952
LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY
EHA Learning Center, Aristoteles Giagounidis, 181953
AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
EHA Learning Center, Saad Z. Usmani, 181963
GENE EXPRESSION CLASSIFIER EMC92/SKY92 AND REVISED ISS ROBUSTLY IDENTIFY HIGH-RISK MULTIPLE MYELOMA IN ELDERLY PATIENTS OF THE HOVON-87/NMSG-18 STUDY
EHA Learning Center, R Kuiper, 181964
MULTIPLE MYELOMA AND COMORBIDITY: A POPULATION-BASED STUDY
EHA Learning Center, Ingigerdur Solveig Sverrisdottir, 181965
DETECTION OF NEW EMERGING CLONES DURING TREATMENT BY NGS ALLOWS A BETTER RISK PREDICTION ON MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Beatriz Sanchez-Vega, 181966
FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY
EHA Learning Center, Andrzej J. Jakubowiak, 181967
PANOBINOSTAT INDUCES CD38 UPREGULATION AND AUGMENTSTHE ANTI-MYELOMA EFFICACY OF DARATUMUMAB
EHA Learning Center, Estefania Garcia-Guerrero, 181968
BCL2 EXPRESSION IS A POTENTIAL PREDICTIVE BIOMARKER OF RESPONSE TO VENETOCLAX IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Jeremy Ross, 181969
QUANTITATIVE PROTEOME HETEROGENEITY IN MYELOPROLIFERATIVE NEOPLASM SUBTYPES AND ASSOCIATION WITH JAK2 MUTATION STATUS
EHA Learning Center, Nuria Socoro Yuste, 181979
THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS
EHA Learning Center, Mathias Schneeweiss, 181980
DISTRIBUTION OF MUTATIONS IN DRIVER AND NON-DRIVER GENES ACCORDING TO CLONAL HEMATOPOIESIS IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA
EHA Learning Center, Alicia Senín, 181981
RUXOLITINIB/NILOTINIB/PREDNISOLONE COMBINATION: A PROMISING NOVEL TREATMENT FOR MYELOFIBROSIS
EHA Learning Center, Joaquin Martinez-Lopez, 181982
INTERLABORATORY ASSESSMENT OF MUTATION DETECTION IN MYELOID MALIGNANCIES BY TARGETED NEXT-GENERATION SEQUENCING
EHA Learning Center, Maria Concepcion Fernandez, 181983
METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE
EHA Learning Center, Suzanne McPherson, 181984
NO IMPROVEMENT IN SURVIVAL OVER TIME FOR PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASM PATIENTS WHO TRANSFORM TO ACCELERATED OR BLAST PHASE
EHA Learning Center, Caroline McNamara, 181995
MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY
EHA Learning Center, Olivier Hermine, 181996
THERAPY RESPONSE AND LONG-TERM OUTCOME OF 71 ADULT PATIENTS WITH HEMATOLOGICAL MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SINGLE INSTITUTION EXPERIENCE
EHA Learning Center, Maciej Machaczka, 181997
WHOLE-EXOME SEQUENCING IN CHILDREN WITH IMMUNE CYTOPENIA: THE APPLICABILITY AND CLINICAL IMPACT
EHA Learning Center, Michael Svaton, 181998
SEQUENCING OF THE HYPOXIA PATHWAY GENES IN PATIENTS WITH CONGENITAL ERYTHROCYTOSES BY NEXT GENERATION SEQUENCING
EHA Learning Center, Francois Girodon, 181999
CHARACTERIZATION OF CD34+ HEMATOPOIETIC PRECURSORS IN INDOLENT SYSTEMIC MASTOCYTOSIS AND THEIR POTENTIAL ROLE IN EARLY DISSEMINATION OF THE DISEASE.
EHA Learning Center, Alberto Orfao, 182000
ATORVASTATIN IMPROVE THE PROGNOSIS OF ADULT PATIENTS WITH CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA VIA ENHANCING BONE MARROW ENDOTHELIAL CELL FUNCTION
EHA Learning Center, Xie Cao, 182012
PLATELET DESIALYLATION IS A NOVEL MECHANISM AND A THERAPEUTIC TARGET IN THROMBOCYTOPENIA DURING SEPSIS: AN OPEN-LABEL, MULTICENTER, RANDOMIZED CONTROLLED TRIAL
EHA Learning Center, Xin Li, 182013
SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)
EHA Learning Center, James Bussel, 182014
IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF CLL PATIENTS RELAPSED/REFRACTORY TO B-CELL RECEPTOR (BCR) SIGNALING PATHWAY INHIBITOR TREATMENT
EHA Learning Center, William Wierda, 182015